Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03710564 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 535
- Enrollment target
NCT03710564 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 535 participants.
The verdict
NCT03710564, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 535 participants
- Enrollment target
Study Summary
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.
Interventions
- BIOLOGICAL Aflibercept
- BIOLOGICAL Brolucizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2021-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03710564
The ClinicalTrials.gov registry entry for NCT03710564 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT03710564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03710564 about?
NCT03710564 is a clinical study titled "Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections". This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF...
What is the current status of trial NCT03710564?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 535 participants. The study started on 2018-10-30. Estimated completion is 2021-07-01.
What interventions are being tested in trial NCT03710564?
The interventions under investigation include: Aflibercept (BIOLOGICAL), Brolucizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03710564?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.